Sorted By Test Name - Mayo Medical Laboratories

OPRMO
60352
haplotype-based approach confirmed that the single OPRM1 355A->G locus was predictive of response
to naltrexone treatment.(1) Frequency of the 355G allele varies with ethnicity but ranges between 10%
and 40% (European 20%, Asian 40%, African American 10%, and Hispanic 25%).
Useful For: Identifying individuals with a higher probability of successful treatment for alcoholism
with naltrexone
Interpretation: An interpretative report will be provided.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Somogyi A, Barratt D, Coller J: Pharmacogenetics of opioids. Clin
Pharmacol Ther 2007;81:429-444 2. Oroszi G, Anton R, Oâ€Malley S, et al: OPRM1 Asn40Asp
predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res
2009;33:383-393 3. Anton R, Oroszi G, Oâ€Malley, et al: An evaluation of mu-opioid receptor
(OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen
Psychiatry 2008;65:135-144 4. Oslin D, Berrettini W, Kranzler H, et al: A functional polymorphism of
the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
Neuropsychopharmacology 2003;28:1546-1552
Opioid Receptor, Mu 1 (OPRM1) Genotype for Naltrexone
Efficacy, Saliva
Clinical Information: The mu-opioid receptor (OPRM1) is the primary binding site of action for
many opioid drugs and for binding of beta-endorphins. One of the effects of opiate and alcohol use is to
increase release of beta-endorphins, which subsequently increases release of dopamine and stimulates
cravings. Naltrexone is an opioid antagonist used to treat abuse of opiates, alcohol, and other substances.
Naltrexone binds to OPRM1, preventing beta-endorphin binding and subsequently reducing the craving
for substances of abuse.(1) The A355G polymorphism (rs1799971) in exon 1 of the OPRM1 gene
(OPRM1) results in an amino acid change, Asn102Asp. Historically, this mutation has been referred to in
the literature as 118A->G (Asn40Asp).(2) The G allele leads to loss of the putative N-glycosylation site in
the extracellular receptor region, causing a decrease in OPRM1 mRNA and protein levels, but a 3-fold
increase in beta-endorphin binding at the receptor.(3) Studies have shown individuals who carry at least 1
G allele have significantly better outcomes with naltrexone therapy including lower rate of relapse
(P=0.044), a longer time to return to heavy drinking, and G locus was predictive of response
to naltrexone treatment.(1) Frequency of the 355G allele varies with ethnicity but ranges between 10%
and 40% (European 20%, Asian 40%, African American 10%, and Hispanic 25%).
Useful For: Identifying individuals with a higher probability of successful treatment for alcoholism
with naltrexone
Interpretation: An interpretative report will be provided.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Somogyi A, Barratt D, Coller J: Pharmacogenetics of Opioids. Clin
Pharmacol Ther 2007;81:429-444 2. Oroszi G, Anton R, O'Malley S, et al: OPRM1 Asn40Asp predicts
response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 2009;33:383-393 3.
Anton R, Oroszi G, O'Malley, et al: An evaluation of mu-opioid receptor (OPRM1) as a predictor of
naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry 2008;65:135-144 4.
Oslin D, Berrettini W, Kranzler H, et al: A functional polymorphism of the mu-opioid receptor gene is
associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology
2003;28:1546-1552
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1336